The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Spectrum Pharmaceuticals (Inst)
Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer.
 
Manik Amin
No Relationships to Disclose
 
Monica Dandona Desai
No Relationships to Disclose
 
Steven Sorscher
Honoraria - Celgene; Genentech; Lilly; Novartis; Pfizer
Speakers' Bureau - Celgene; Genentech; Lilly
 
Kian-Huat Lim
No Relationships to Disclose
 
Andrea Wang-Gillam
Consulting or Advisory Role - Merrimack
Research Funding - Aduro Biotech (Inst); EMD Serono (Inst); Merrimack (Inst); Millennium (Inst); OncoMed (Inst); Pfizer (Inst); Prometheus (Inst)
 
Benjamin R. Tan
No Relationships to Disclose
 
Joel Picus
No Relationships to Disclose
 
Maureen Highkin
Stock and Other Ownership Interests - Pfizer
 
Kimberly Lears
No Relationships to Disclose
 
Albert C. Lockhart
Research Funding - Amgen (Inst); Bayer (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Lilly (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Teva (Inst); Zenyaku Kogyo (Inst)